20 citations
,
November 2017 in “JAAD case reports” This case report describes a patient with psoriasis, vitiligo, and alopecia areata who showed significant improvement in all conditions after treatment with ustekinumab, suggesting potential benefits of IL-12/23 blockade for these autoimmune diseases.
8 citations
,
June 2024 in “Pharmaceutics” This study found that using elastic nano-liposomes to deliver palmitoylethanolamide improved its transdermal delivery and enhanced its skincare effects, with minimal cytotoxicity and no allergic reactions observed.
January 2026 in “Dermatologic Therapy” This study reports that intramuscular compound betamethasone may offer rapid, short-term reduction in hair shedding for patients with telogen effluvium, particularly within a week, but often requires repeated treatments; only mild side effects were observed.
July 2025 in “Current Issues in Molecular Biology” This study evaluated the safety and efficacy of Bio-Pulsed avian mesenchymal stem cell-derived small extracellular vesicles when applied topically, finding significant improvements in hair growth, skin rejuvenation, and regenerative microRNA presence among 60 human participants without adverse events.
76 citations
,
May 2007 in “Menopause International” This review discusses the relationship between estrogen deficiency and skin aging in postmenopausal women, noting potential benefits of estrogen use on skin collagen and elasticity, but reports no new clinical results.
7 citations
,
November 1997 in “Reproduction Fertility and Development” In this study, subcutaneous injections of murine epidermal growth factor in marsupial pouch young inhibited the formation of hair follicles and associated structures, altering normal follicle development.
20 citations
,
January 2000 in “Dermatologic Clinics” This article discusses recent advancements in treatments for psoriasis, including new drug approvals and innovative therapeutic approaches, but reports no new clinical results.
8 citations
,
January 2025 in “Cell Transplantation” This review discusses the advances and challenges of using mesenchymal stem cell-derived extracellular vesicles in therapeutic applications and reports no new clinical findings.
2 citations
,
May 2025 in “Frontiers in Pharmacology” In this study, analysis of FDA data revealed a substantial risk of dermatologic adverse events with aromatase inhibitors, especially anastrozole and exemestane, highlighting the importance of dermatologic monitoring during such therapies.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This document promotes a 25% discount using the code AVA25 on Erthwellness's natural health supplements, detailing how to apply the code and the benefits of their products, with no new research findings reported.
68 citations
,
January 2014 in “Dermatology research and practice” This review discusses the presentation and management of skin toxicity from epidermal growth factor inhibitors, highlighting a correlation between cutaneous adverse effects and tumor response, but reports no new clinical results.
2 citations
,
September 2022 in “Annals of Oncology” This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.
65 citations
,
September 1999 in “The Journal of Dermatology” In this study, complete to excellent hair regrowth was observed in 63.3% of patients with extensive alopecia areata treated with biweekly dexamethasone pulses, although mild side effects were frequent.
August 2025 in “Annals of Medicine” This review discusses recent advances in using extracellular vesicles as a potential treatment for alopecia and highlights ongoing challenges in their clinical application and mass production; no new clinical results are reported.
May 2025 in “Frontiers in Bioengineering and Biotechnology” In this study, the researchers reported that a novel exosome-based treatment, EX104, effectively reversed hair follicle miniaturization and promoted hair growth in a mouse model of androgenetic alopecia, showing results comparable to minoxidil and surpassing it in stimulating capillary growth and follicular proliferation.
17 citations
,
April 2016 in “Journal of Investigative Dermatology” This study found that the synthetic thyroid hormone receptor modulator KB2115 significantly prolonged the growth phase of human hair follicles in culture without altering mitochondrial activity, suggesting potential as a safer hair loss treatment compared to traditional thyroid hormones.
36 citations
,
May 2017 in “The journal of sexual medicine” In this retrospective study, cyproterone acetate treatment in late-pubertal trans-girls was found to be generally safe and led to mild feminizing effects, with more rapid feminization occurring when combined with estrogens.
October 2025 in “Journal of the Endocrine Society” This research review observed that topical hormone replacement therapy, particularly estradiol and estradiol-testosterone combinations, significantly increased Type I and III collagen synthesis in the skin of postmenopausal women, suggesting benefits against collagen loss-related skin aging effects such as reduced elasticity and increased dryness.
August 2025 in “JEADV Clinical Practice” This case report describes the management of PRIDE complex, a skin and hair condition associated with EGFR inhibitor treatment like cetuximab, emphasizing that it does not require stopping the medication.
1 citations
,
September 2025 in “International Journal of Drug Delivery Technology” This randomized controlled study reported that combining Ecklonia cava with Diane-35 significantly improved weight, waist circumference, hormonal balance, and inflammation markers in women with polycystic ovary syndrome over three months compared to Diane-35 alone.
35 citations
,
October 2005 in “European journal of pharmaceutics and biopharmaceutics” This study found that polymers significantly improved the chemical and microbial stability of steroid hormones in liposome formulations over eight weeks, with finasteride showing the highest diffusion rate.
May 2015 in “Journal of The American Academy of Dermatology” A heart transplant patient developed a skin condition called epidermodysplasia verruciformis after taking immune-suppressing drugs.
December 2024 in “PubMed” This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.
1 citations
,
January 2023 in “Cutis” This report discusses two cases where patients continued EGFR inhibitor therapy while receiving topical treatments for SDRIFE, highlighting the importance of dermatologists in managing such cutaneous adverse events without stopping cancer treatment.
306 citations
,
August 2011 in “Journal of cachexia, sarcopenia and muscle” This study found that GTx-024 significantly increased total lean body mass and improved physical function in healthy elderly men and postmenopausal women, suggesting potential use for muscle wasting conditions.
16 citations
,
February 2009 in “Clinical neurology and neurosurgery” In this study, patients with epilepsy who switched from immediate-release to extended-release divalproex sodium did not experience significant changes in seizure frequency, but most preferred the new formulation due to a subjective decrease in tremor during daily activities.
9 citations
,
December 2021 in “Actas Dermo-Sifiliográficas” This review discusses the characteristics and treatment recommendations for skin-related adverse effects from immune checkpoint inhibitors in cancer treatment, and notes an observed association with favorable oncology outcomes that requires careful interpretation.
In this study, latanoprost was found to stimulate VEGF protein synthesis in human dermal papilla cells, suggesting it may contribute to promoting hair growth.
1 citations
,
January 2014 In this study, the release rate of Finasteride from Eudragit matrix tablets was found to be significantly influenced by the drug/Eudragit ratio and polymer viscosity, with formulation F9 being the most effective.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.